Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy - PubMed
8 days ago
- #CAR T-cell therapy
- #prognostic significance
- #large B-cell lymphoma
- Study focuses on disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma and its prognostic significance for real-world outcomes.
- Bridging therapy does not affect the prognostic significance of disease status at CAR T-cell infusion.
- Multiple authors received honoraria and research funding from various pharmaceutical companies, indicating potential conflicts of interest.
- The study was conducted in accordance with ethical guidelines, including the Declaration of Helsinki, and received approval from relevant ethics committees.
- References include studies on bridging therapy's impact on CAR-T outcomes and metabolic tumor volume's effect on treatment efficacy.